NRIX
Nurix Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$22.71-1.77%
Price as of Jul 20, 2026
NRIX profitability
Nurix Therapeutics, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- -165.5%
- EBITDA margin
- -869.6%
- EBIT margin
- -982.4%
- Net margin
- -928.4%
- Free cash flow margin
- -828.3%
Returns
- Return on equity
- -84.8%
- Return on assets
- -63.7%
- Return on invested capital
- -78.4%
- Asset turnover
- 0.06x
Cash efficiency
- Cash from operations
- -$293.7M
- Cash per share
- $4.29
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.